U.S. patent application number 15/870380 was filed with the patent office on 2018-06-28 for method and medicament for inhibiting the expression of a given gene.
The applicant listed for this patent is Alnylam Pharmaceuticals, Inc.. Invention is credited to Roland Kreutzer, Stefan Limmer.
Application Number | 20180179526 15/870380 |
Document ID | / |
Family ID | 26051592 |
Filed Date | 2018-06-28 |
United States Patent
Application |
20180179526 |
Kind Code |
A1 |
Kreutzer; Roland ; et
al. |
June 28, 2018 |
Method and Medicament For Inhibiting The Expression of A Given
Gene
Abstract
The invention relates to an isolated RNA that mediates RNA
interference of an mRNA to which it corresponds and a method of
mediating RNA interference of mRNA of a gene in a cell or organism
using the isolated RNA.
Inventors: |
Kreutzer; Roland;
(Weidenberg, DE) ; Limmer; Stefan; (Kulmbach,
DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Alnylam Pharmaceuticals, Inc. |
Cambridge |
MA |
US |
|
|
Family ID: |
26051592 |
Appl. No.: |
15/870380 |
Filed: |
January 12, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13656548 |
Oct 19, 2012 |
9902954 |
|
|
15870380 |
|
|
|
|
11982325 |
Oct 31, 2007 |
|
|
|
13656548 |
|
|
|
|
10612179 |
Jul 2, 2003 |
8202980 |
|
|
11982325 |
|
|
|
|
09889802 |
Sep 17, 2001 |
|
|
|
PCT/DE2000/000244 |
Jan 29, 2000 |
|
|
|
10612179 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 25/28 20180101;
C12N 2310/111 20130101; A61P 31/12 20180101; A61P 31/20 20180101;
A61K 38/00 20130101; C12N 15/113 20130101; Y02A 50/30 20180101;
C12N 2310/14 20130101; A61P 31/04 20180101; C12N 2330/30 20130101;
A61P 31/00 20180101; C12N 15/111 20130101; Y02A 50/411 20180101;
C12N 2310/53 20130101; A61P 35/00 20180101; A61P 43/00 20180101;
A61K 31/713 20130101; A61P 31/10 20180101; Y02A 50/467
20180101 |
International
Class: |
C12N 15/113 20060101
C12N015/113; C12N 15/11 20060101 C12N015/11 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 30, 1999 |
DE |
DE19903713.2 |
Nov 24, 1999 |
DE |
DE19956568.6 |
Claims
1. An oligoribonucleotide of double-stranded structure (dsRNA) for
inhibiting the expression of a given target gene in mammalian
cells, wherein the dsRNA has 15-49 base pairs comprising at least
one 2'-modified nucleotide, and wherein the dsRNA has a
complementary region I that is incorporated in the dsRNA.
2. The dsRNA of claim 1, wherein the complementary region I is
15-49 nucleotide pairs.
3. The dsRNA of claim 1, wherein the 2'-modified nucleotide is a
2'-methyl substituted nucleotide.
4. The dsRNA of claim 1, wherein the 2'-modified nucleotide is a
2'-amino substituted nucleotide.
5. The dsRNA of claim 1, wherein the 2'-modified nucleotide is a
locked nucleotide.
6. The dsRNA of claim 1, wherein the at least one 2'-modified
nucleotide is at the 3' terminus of the dsRNA.
7. The dsRNA of claim 1, further comprising at least one
thiophosphoryl group at the 3' terminus of the dsRNA.
8. The dsRNA of claim 7, wherein both the at least one 2'-modified
nucleotide and the at least one thiophosphoryl group are at the 3'
terminus of the dsRNA.
9. The dsRNA of claim 1, wherein the at least one 2'-modified
nucleotide is at the 5'terminus of the dsRNA.
10. The dsRNA of claim 1, further comprising at least one
thiophosphoryl group at the 5'terminus of the dsRNA.
11. The dsRNA of claim 10, wherein both the at least one
2'-modified nucleotide and the at least one thiophosphoryl group
are at the 5'terminus of the dsRNA.
12. The dsRNA of claim 1, wherein the target gene is a mammalian
gene or a viral gene.
13. The dsRNA of claim 1, wherein the target gene is selected from
the group consisting of an oncogene, a cytokine gene, an Id protein
gene, a developmental gene, a PKR gene, and a prion gene.
14. The dsRNA of claim 1, wherein the dsRNA is enclosed by a
micellar structure.
15. The dsRNA of claim 14, wherein the micellar structure comprises
a liposome.
16. The dsRNA of claim 1, wherein the target gene is expressed in
eukaryotic cells.
17. The dsRNA of claim 1, wherein an end of the dsRNA is modified
in order for the double-stranded structure to counteract
degradation.
18. The dsRNA of claim 1, wherein the dsRNA comprises a sense
strand and an antisense strand, and wherein the sense strand
comprises a 2'-methyl substituted nucleotide.
19. The dsRNA of claim 1, wherein the dsRNA comprises a sense
strand and an antisense strand, and wherein the sense strand
comprises a 2'-methoxynucleotide.
20. The dsRNA of claim 1, wherein the dsRNA comprises a sense
strand and an antisense strand, and wherein the sense strand
comprises a plurality of 2'-methoxynucleotides.
21. The dsRNA of claim 1, wherein the dsRNA comprises two strands,
one of the two strands being complementary to less than the full
length of a third strand that comprises an RNA transcript, and
wherein the dsRNA is capable of reducing an amount of the third
strand in response to the dsRNA being introduced into the presence
of the third strand in a mammalian cell, the dsRNA thereby being
capable of specifically inhibiting expression of the given target
gene.
22. The dsRNA of claim 1, wherein the dsRNA comprises a
pharmaceutical composition formulated for delivery to a mammalian
cell.
23. A pharmaceutical composition comprising an oligoribonucleotide
of double-stranded structure (dsRNA) for inhibiting the expression
of a given target gene in mammalian cells, wherein the dsRNA has
15-49 base pairs comprising at least one 2'-modified nucleotide,
and wherein the dsRNA has a complementary region I that is
incorporated in the dsRNA.
24. The pharmaceutical composition of claim 23, further comprising
a liposome enclosing the dsRNA for delivery to a mammalian
cell.
25. The pharmaceutical composition of claim 23, further comprising
at least one other different dsRNA.
26. The pharmaceutical composition of claim 23, wherein the
2'-modified nucleotide is a locked nucleotide.
27. The pharmaceutical composition of claim 23, wherein the at
least one 2'-modified nucleotide is at the 3' terminus of the
dsRNA.
28. The pharmaceutical composition of claim 23, further comprising
at least one thiophosphoryl group at the 3' terminus of the
dsRNA.
29. The pharmaceutical composition of claim 28, wherein both the at
least one 2'-modified nucleotide and the at least one
thiophosphoryl group are at the 3' terminus of the dsRNA.
30. The pharmaceutical composition of claim 23, wherein the at
least one 2'-modified nucleotide is at the 5'terminus of the
dsRNA.
31. The pharmaceutical composition of claim 23, further comprising
at least one thiophosphoryl group at the 5'terminus of the
dsRNA.
32. The pharmaceutical composition of claim 31, wherein both the at
least one 2'-modified nucleotide and the at least one
thiophosphoryl group are at the 5'terminus of the dsRNA.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 13/656,548, filed Oct. 19, 2012, now allowed,
which is a continuation of U.S. patent application Ser. No.
11/982,325, filed Oct. 31, 2007, now abandoned, which is a
continuation of U.S. patent application Ser. No. 10/612,179, filed
Jul. 2, 2003, now U.S. Pat. No. 8,202,980, issued Jun. 19, 2012,
which is a divisional of U.S. patent application Ser. No.
09/889,802, filed Sep. 17, 2001, now abandoned, which is the
National Stage of International Patent Application No.
PCT/DE2000/00244, filed Jan. 29, 2000, which claims priority to
German Patent Application No. DE19903713.2, filed Jan. 30, 1999,
and German Patent Application No. DE19956568.6, filed Nov. 24,
1999. The contents of these prior applications are hereby
incorporated by reference in their entirety for all purposes.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted via EFS-Web and is hereby incorporated by
reference in its entirety. Said ASCII copy, created on Nov. 29,
2017, is named 39294 US_CRF_sequencelisting.txt, and is 8,192 bytes
in size.
[0003] The invention relates to a medicament and to a use of
double-stranded oligoribonucleotides and to a vector encoding
them.
[0004] Such a method is known from WO 99/32619, which was
unpublished at the priority date of the present invention. The
known process aims at inhibiting the expression of genes in cells
of invertebrates. To this end, the double-stranded
oligoribonucleotide must exhibit a sequence which is identical with
the target gene and which has a length of at least 50 bases. To
achieve efficient inhibition, the identical sequence must be 300 to
1000 base pairs in length. Such an oligoribonucleotide is
complicated to prepare.
[0005] DE 196 31 919 C2 describes an antisense RNA with specific
secondary structures, the antisense RNA being present in the form
of a vector encoding it. The antisense RNA takes the form of an RNA
molecule which is complementary to regions of the mRNA. Inhibition
of the gene expression is caused by binding to these regions. This
inhibition can be employed in particular for the diagnosis and/or
therapy of diseases, for example tumor diseases or viral
infections.--The disadvantage is that the antisense RNA must be
introduced into the cell in an amount which is at least as high as
the amount of the mRNA. The known antisense methods are not
particularly effective.
[0006] U.S. Pat. No. 5,712,257 discloses a medicament comprising
mismatched double-stranded RNA (dsRNA) and bioactive mismatched
fragments of dsRNA in the form of a ternary complex together with a
surfactant. The dsRNA used for this purpose consists of synthetic
nucleic acid single strands without defined base sequence. The
single strands undergo irregular base pairing, also known as
"non-Watson-Crick" base pairing, giving rise to mismatched double
strands. The known dsRNA is used to inhibit the amplification of
retroviruses such as HIV. Amplification of the virus can be
inhibited when non-sequence-specific dsRNA is introduced into the
cells. This leads to the induction of interferon, which is intended
to inhibit viral amplification. The inhibitory effect, or the
activity, of this method is poor.
[0007] It is known from Fire, A. et al., NATURE, Vol. 391, pp. 806
that dsRNA whose one strand is complementary in segments to a
nematode gene to be inhibited inhibits the expression of this gene
highly efficiently. It is believed that the particular activity of
the dsRNA used in nematode cells is not due to the antisense
principle but possibly on catalytic properties of the dsRNA, or
enzymes induced by it.--Nothing is mentioned in this paper on the
activity of specific dsRNA with regard to inhibiting the gene
expression, in particular in mammalian and human cells.
[0008] The object of the present invention is to do away with the
disadvantages of the prior art. In particular, it is intended to
provide as effective as possible a method, medicament or use for
the preparation of a medicament, which method, medicament or use is
capable of causing particularly effective inhibition of the
expression of a given target gene.
[0009] This object is achieved by the features of the claims
presented here. Advantageous embodiments can be seen from the
claims presented here.
[0010] In accordance with the method-oriented inventions, it is
provided in each case that the region I which is complementary to
the target gene exhibits not more than 49 successive nucleotide
pairs.
[0011] Provided in accordance with the invention are an
oligoribonucleotide or a vector encoding therefor. At least
segments of the oligoribonucleotide exhibit a defined nucleotide
sequence. The defined segment may be limited to the complementary
region I. However, it is also possible that all of the
double-stranded oligoribonucleotide exhibits a defined nucleotide
sequence.
[0012] Surprisingly, it has emerged that an effective inhibition of
the expression of the target gene can be achieved even when the
complementary region I is not more than 49 base pairs in length.
The procedure of providing such oligoribonucleotides is less
complicated.
[0013] In particular, dsRNA with a length of over 50 nucleotide
pairs induces certain cellular mechanisms, for example the
dsRNA-dependent protein kinase or the 2-5 A system, in mammalian
and human cells. This leads to the disappearance of the
interference effect mediated by the dsRNA which exhibits a defined
sequence. As a consequence, protein biosynthesis in the cell is
blocked. The present invention overcomes this disadvantage in
particular.
[0014] Furthermore, the uptake of dsRNA with short chain lengths
into the cell or into the nucleus is facilitated markedly over
longer-chain dsRNAs.
[0015] It has proved advantageous for the dsRNA or the vector to be
present packaged into micellar structures, preferably in liposomes.
The dsRNA or the vector can likewise be enclosed in viral natural
capsids or in chemically or enzymatically produced artificial
capsids or structures derived therefrom. The abovementioned
features make it possible to introduce the dsRNA or the vector into
given target cells.
[0016] In a further aspect, the dsRNA has 10 to 1000, preferably 15
to 49, base pairs. Thus, the dsRNA can be longer than the region I,
which is complementary to the target gene. The complementary region
I can be located at the terminus or inserted into the dsRNA. Such
dsRNA or a vector provided for coding the same can be produced
synthetically or enzymatically by customary methods.
[0017] The gene to be inhibited is expediently expressed in
eukaryotic cells. The target gene can be selected from the
following group: oncogene, cytokin gene, Id protein gene,
developmental gene, prion gene. It can also be expressed in
pathogenic organisms, preferably in plasmodia. It can be part of a
virus or viroid which is preferably pathogenic to humans.--The
method proposed makes it possible to produce compositions for the
therapy of genetically determined diseases, for example cancer,
viral diseases or Alzheimer's disease.
[0018] The virus or viroid can also be a virus or viroid which is
pathogenic to animals or plant-pathogenic. In this case, the method
according to the invention also permits the provision of
compositions for treating animal or plant diseases.
[0019] In a further aspect, segments of the dsRNA are designed as
double-stranded. A region II which is complementary within the
double-stranded structure is formed by two separate RNA single
strands or by autocomplementary regions of a topologically closed
RNA single strand which is preferably in circular form.
[0020] The ends of the dsRNA can be modified to counteract
degradation in the cell or dissociation into the single strands.
Dissociation takes place in particular when low concentrations or
short chain lengths are used. To inhibit dissociation in a
particularly effective fashion, the cohesion of the complementary
region II, which is caused by the nucleotide pairs, can be
increased by at least one, preferably two, further chemical
linkage(s).--A dsRNA according to the invention whose dissociation
is reduced exhibits greater stability to enzymatic and chemical
degradation in the cell or in the organism.
[0021] The complementary region II can be formed by
autocomplementary regions of an RNA hairpin loop, in particular
when using a vector according to the invention. To afford
protection from degradation, it is expedient for the nucleotides to
be chemically modified in the loop region between the
double-stranded structure.
[0022] The chemical linkage is expediently formed by a covalent or
ionic bond, a hydrogen bond, hydrophobic interactions, preferably
van-der-Waals or stacking interactions, or by metal-ion
coordination. In an especially advantageous aspect, it can be
formed at at least one, preferably both, end(s) of the
complementary region II.
[0023] It has furthermore proved to be advantageous for the
chemical linkage to be formed by one or more linkage groups, the
linkage groups preferably being poly (oxyphosphinicooxy-1,
3-propanediol) and/or poly-ethylene glycol chains. The chemical
linkage can also be formed by purine analogs used in place of
purines in the complementary regions II. It is also advantageous
for the chemical linkage to be formed by azabenzene units
introduced into the complementary regions II. Moreover, it can be
formed by branched nucleotide analogs used in place of nucleotides
in the complementary regions II.
[0024] It has proved expedient to use at least one of the following
groups for generating the chemical linkage: methylene blue;
bifunctional groups, preferably bis (2-chloroethyl) amine;
N-acetyl-N'-(p-glyoxyl-benzoyl) cystamine; 4-thiouracil; psoralene.
The chemical linkage, can furthermore be formed by thiophosphoryl
groups provided at the ends of the double-stranded region. The
chemical linkage at the ends of the double-stranded region is
preferably formed by triple-helix bonds.
[0025] The chemical linkage can expediently be induced by
ultraviolet light.
[0026] The nucleotides of the dsRNA can be modified. This
counteracts the activation, in the cell, of a
double-stranded-RNA-dependent protein kinase, PKR. Advantageously,
at least one 2'-hydroxyl group of the nucleotides of the dsRNA in
the complementary region II is replaced by a chemical group,
preferably a 2'-amino or a 2'-methyl group. At least one nucleotide
in at least one strand of the complementary region II can also be a
locked nucleotide with a sugar ring which is chemically modified,
preferably by a 2'-O, 4'-C methylene bridge. Advantageously,
several nucleotides are locked nucleotides.
[0027] A further especially advantageous embodiment provides that
the dsRNA or the vector is bound to, associated with or surrounded
by, at least one viral coat protein which originates from a virus,
is derived therefrom or has been prepared synthetically. The coat
protein can be derived from polyomavirus. The coat protein can
contain the polyomavirus virus protein 1 (VP1) and/or virus protein
2 (VP2). The use of such coat proteins is known from, for example,
DE 196 18 797 A1, whose disclosure is herewith incorporated.--The
abovementioned features considerably facilitate the introduction of
the dsRNA or of the vector into the cell.
[0028] When a capsid or capsid-type structure is formed from the
coat protein, one side preferably faces the interior of the capsid
or capsid-type structure. The construct formed is particularly
stable.
[0029] The dsRNA can be complementary to the primary or processed
RNA transcript of the target gene.--The cell can be a vertebrate
cell or a human cell.
[0030] At least two dsRNAs which differ from each other or at least
one vector encoding them can be introduced into the cell, where at
least segments of one strand of each dsRNA are complementary to in
each case one of at least two different target genes. This makes it
possible simultaneously to inhibit the expression of at least two
different target genes. In order to suppress, in the cell, the
expression of a double-stranded-RNA-dependent protein kinase, PKR,
one of the target genes is advantageously the PKR gene. This allows
effective suppression of the PKR activity in the cell.
[0031] The invention furthermore provides a medicament with at
least one oligoribonucleotide with double-stranded structure
(dsRNA) for inhibiting the expression of a given target gene, where
one strand of the dsRNA has a region I where at least segments are
complementary to the target gene.--Surprisingly, it has emerged
that such a dsRNA is suitable as medicament for inhibiting the
expression of a given gene in mammalian cells. In comparison with
the use of single-stranded oligoribonucleotides, the inhibition is
already caused at concentrations which are lower by at least one
order of magnitude. The medicament according to the invention is
highly effective. Lesser side effects can be expected.
[0032] The invention furthermore provides a medicament with at
least one vector for coding at least one oligoribonucleotide with
double-stranded structure (dsRNA) for inhibiting the expression of
a given target gene, where one strand of the dsRNA has a region I
where at least segments are complementary to the target gene.--The
medicament proposed exhibits the abovementioned advantages. By,
using a vector, in particular production costs can be reduced.
[0033] In a particularly advantageous embodiment, the complementary
region I has not more than 49 successive nucleotide
pairs.--Surprisingly, it has emerged that an effective inhibition
of the expression of the target gene can be achieved even when the
complementary region I is not more than 49 base pairs in length.
The procedure of providing such oligoribonucleotides is less
complicated.
[0034] The invention furthermore provides a use of an
oligoribonucleotide with double-stranded structure (dsRNA) for
preparing a medicament for inhibiting the expression of a given
target gene, where one strand of the dsRNA has a region I where at
least segments are complementary to the target gene.--Surprisingly,
such a dsRNA is suitable for preparing a medicament for inhibiting
the expression of a given gene. Compared with the use of
single-stranded oligoribonucleotides, the inhibition is already
caused at concentrations which are lower by one order of magnitude
when using dsRNA. The use according to the invention thus makes
possible the preparation of particularly effective medicaments.
[0035] The invention furthermore provides the use of a vector for
coding at least one oligoribonucleotide with double-stranded
structure (dsRNA) for preparing a medicament for inhibiting the
expression of a given target gene, where one strand of the dsRNA
has a region I where at least segments are complementary to this
target gene.--The use of a vector makes possible a particularly
effective gene therapy.
[0036] With regard to advantageous embodiments of the medicament
and of the use, reference is made to the description of the above
features.
[0037] Use examples of the invention are illustrated in greater
detail hereinbelow with reference to the figures, in which:
[0038] FIG. 1 shows the schematic representation of a plasmid for
the in vitro, transcription with T7- and SP6-polymerase,
[0039] FIG. 2 shows RNA following electrophoresis on an 8%
polyacrylamide gel and staining with ethidium bromide,
[0040] FIG. 3 shows a representation of radioactive RNA transcripts
following electrophoresis on an 8% polyacrylamide gel with 7 M urea
by means of an instant imager, and
[0041] FIGS. 4a-e show Texas Red and YFP. fluorescence in murine
fibroblasts.
USE EXAMPLE 1
[0042] The inhibition of transcription was detected by means of
sequence homologous dsRNA in an in vitro transcription system with
a nuclear extract from human HeLa cells. The DNA template for this
experiment was plasmid pCMV1200 which had been linearized by means
of BamHI.
Generation of the Template Plasmids:
[0043] The plasmid shown in FIG. 1 was constructed for use in the
enzymatic synthesis of the dsRNA. To this end, a polymerase chain
reaction (PCR) with the "positive control DNA" of the
HelaScribe.RTM. Nuclear Extract in vitro transcription kit by
Promega, Madison, USA, as DNA template was first carried out. One
of the primers used contained the sequence of an EcoRI cleavage
site and of the T7 RNA polymerase promoter as shown in sequence
listing No. 1. The other primer contained the sequence of a BamHI
cleavage site and of the SP6 RNA polymerase promoter as shown in
sequence listing No. 2. In addition, the two primers had, at the 3'
ends, regions which were identical with or complementary to the DNA
template. The PCR was carried out by means of the "Taq PCR Core
Kits" by Qiagen, Hilden, Germany, following the manufacturer's
instructions. 1.5 mM MgCl.sub.2, in each case 200 .mu.M dNTP, in
each case 0.5 .mu.M primer, 2.5 U Taq DNA polymerase and
approximately 100 ng of "positive control DNA" were employed as
template in PCR buffer in a volume of 100 .mu.l. After initial
denaturation of the template DNA by heating for 5 minutes at
94.degree. C., amplification was carried out in 30 cycles of
denaturation for in each case 60 seconds at 94.degree. C.,
annealing for 60 seconds at 5.degree. C. below the calculated
melting point of the primers and polymerization for 1.5-2 minutes
at 72.degree. C. After a final polymerization of 5 minutes at
72.degree. C., 5 .mu.l of the reaction were analyzed by agarose-gel
electrophoresis. The length of the DNA fragment amplified thus was
400 base pairs, 340 base pairs corresponding to the "positive
control DNA". The PCR product was purified, hydrolyzed with EcoRI
and BamHI and, after repurification, employed in the ligation
together with a pUC18 vector which had also been hydrolyzed by
EcoRI and BamHI. E. coli XL 1-blue was then transformed. The
plasmid obtained (pCMV5) carries a DNA fragment whose 5' end is
flanked by the T7 promoter and whose 3' end is flanked by the SP6
promoter. By linearizing the plasmid with BamHI, it can be employed
in vitro with the T7-RNA polymerase for the run-off transcription
of a single-stranded RNA which is 340 nucleotides in length and
shown in sequence listing No. 3. If the plasmid is linearized with
EcoRI, it can be employed for the run-off transcription with SP6
RNA polymerase, giving rise to the complementary strand. In
accordance with the method outlined hereinabove, an RNA 23
nucleotides in length was also synthesized. To this end, a DNA
shown in sequence listing No. 4 was ligated with the pUC18 vector
via the EcoRI and BamHI cleavage sites.
[0044] Plasmid pCMV1200 was constructed as DNA template for the
in-vitro transcription with HeLa nuclear extract. To this end, a 1
191 bp EcoRI/BamHI fragment of the positive control DNA contained
in the HeLaScribe.RTM. Nuclear Extract in vitro transcription kit
was amplified by means of PCR. The amplified fragment encompasses
the 828 by "immediate early" CMV promoter and a 363 by
transcribable DNA fragment. The PCR product was ligated to the
vector pGEM-T via "T-overhang" ligation. A BamHI cleavage site is
located at the 5' end of the fragment. The plasmid was linearized
by hydrolysis with BamHI and used as template in the run-off
transcription.
In-Vitro Transcription of the Complementary Single Strands:
[0045] pCMV5 plasmid DNA was linearized with EcoRI or BamHI. It was
used as DNA template for an in-vitro transcription of the
complementary RNA single strands with SP6 and T7 RNA polymerase,
respectively. The "Riboprobe in vitro Transcription" system by
Promega, Madison, USA, was employed for this purpose. Following the
manufacturer's instructions, 2 .mu.g of linearized plasmid DNA were
incubated in 100 .mu.l of transcription buffer and 40 U T7 or SP6
RNA polymerase for 5-6 hours at 37.degree. C. The DNA template was
subsequently degraded by addition of 2.5 .mu.l of RNase-free DNase
RQ1 and incubation for 30 minutes at 37.degree. C. The
transcription reaction was made up to 300 .mu.l with H.sub.2O and
purified by phenol extraction. The RNA was precipitated by addition
of 150 .mu.l of 7 M ammonium acetate [sic] and 1 125 .mu.l of
ethanol and stored at -65.degree. C. until used for the
hybridization.
Generation of the RNA Double Strands:
[0046] For the hybridization, 500 .mu.l of the single-stranded RNA
which had been stored in ethanol and precipitated were spun down.
The resulting pellet was dried and taken up in 30 .mu.l of PIPES
buffer, pH 6.4 in the presence of 80% formamide, 400 mM NaCl and 1
mM EDTA. In each case 15 .mu.l of the complementary single strands
were combined and heated for 10 minutes at 85.degree. C. The
reactions were subsequently incubated overnight at 50.degree. C.
and cooled to room temperature.
[0047] Only approximately equimolar amounts of the two single
strands were employed in the hybridization. This is why the dsRNA
preparations contained single-stranded RNA (ssRNA) as contaminant.
In order to remove these ssRNA contaminants, the reactions were
treated, after hybridization, with the single-strand-specific
ribonucleases bovine pancreatic RNase A and Aspergillus oryzae
RNase T1. RNase A is an endoribonuclease which is specific for
pyrimidines. RNase T1 is an endoribonuclease which preferentially
cleaves at the 3' side of guanosines. dsRNA is no substrate for
these ribonucleases. For the RNase treatment, the reactions in 300
.mu.l of Tris, pH 7.4, 300 mM NaCl and 5 mM EDTA were treated with
1.2 .mu.l of RNaseA at a concentration of 10 mg/ml and 2 .mu.l of
RNaSeT1 at a concentration of 290 .mu.g/ml. The reactions were
incubated for 1.5 hours at 30.degree. C. Thereupon, the RNases were
denatured by addition of 5 .mu.l of proteinase K at a concentration
of 20 mg/ml and 10 .mu.l of 20% SDS and incubation for 30 minutes
at 37.degree. C. The dSRNA was purified by phenol extraction and
precipitated with ethanol. To verify the completeness of the RNase
digestion, two control reactions were treated with ssRNA
analogously to the hybridization reactions.
[0048] The dried pellet was taken up in 15 .mu.l of TE buffer, pH
6.5, and subjected to native polyacrylamide gel electrophoresis on
an 8% gel. The acrylamide gel was subsequently stained in an
ethidium bromide solution and washed in a water bath. FIG. 2 shows
the RNA which had been visualized in a UV transilluminator. The
sense RNA which had been applied to lane 1 and the antisense RNA
which had been applied to lane 2 showed a different migration
behavior under the chosen conditions than the dsRNA of the
hybridization reaction which had been applied to lane 3. The
RNase-treated sense RNA and antisense RNA which had been applied to
lanes 4 and 5, respectively, produced no visible band. This shows
that the single-stranded RNAs had been degraded completely. The
RNase-treated dsRNA of the hybridization reaction which had been
applied to lane 6 is resistant to RNase treatment. The band which
migrates faster in the native gel in comparison with the dsRNA
applied to lane 3 results from dsRNA which is free from ssRNA. In
addition to the dominant main band, weaker bands which migrate
faster are observed after the RNase treatment.
In-Vitro Transcription Test with Human Nuclear Extract:
[0049] Using the HeLaScribe.RTM. Nuclear Extract in vitro
transcription kit by Promega, Madison, USA, the transcription
efficiency of the abovementioned DNA fragment which is present in
plasmid pCMV1200 and homologous to the "positive control DNA" was
determined in the presence of the dsRNA (dsRNA-CMV5) with sequence
homology. Also, the effect of the dsRNA without sequence homology,
which corresponds to the yellow fluorescent protein (YFP) gene
(dsRNA-YRP), was studied. This dsRNA had been generated analogously
to the dsRNA with sequence homology. The sequence of a strand of
this dsRNA can be found in sequence listing No. 5. Plasmid pCMV1200
was used as template for the run-off transcription. It carries the
"immediate early" cytomegalovirus promoter which is recognized by
the eukaryotic RNA polymerase II, and a transcribable DNA fragment.
Transcription was carried out by means of the HeLa nuclear extract,
which contains all the proteins which are necessary for
transcription. By addition of [.cndot.-.sup.32P] rGTP to the
transcription reaction, radiolabeled transcript was obtained. The
[.cndot.-.sup.32P] rGTP used had a specific activity of 400
Ci/mmol, 10 mCi/ml. 3 mM MgCl.sub.2, in each case 400 .mu.M rATP,
rCTP, rUTP, 16 .mu.M rGTP, 0.4 .mu.M [.cndot.-.sup.32P] rGTP and
depending on the experiment 1 fmol of linearized plasmid DNA and
various amounts of dsRNA in transcription buffer were employed per
reaction. Each batch was made up to a volume of 8.5 .mu.l with
H.sub.2O. The reactions were mixed carefully. To start the
transcription, 4 U HeLa nuclear extract in a volume of 4 .mu.l were
added and incubated for 60 minutes at 30.degree. C. The reaction
was stopped by addition of 87.5 .mu.l of quench mix which had been
warmed to 30.degree. C. To remove the proteins, the reactions were
treated with 100 .mu.l of phenol/chloroform/isoamyl alcohol
(25:24:1 v/v/v) saturated with TE buffer, pH 5.0, and the reactions
were mixed vigorously for 1 minute. For phase separation, the
reactions were spun for approximately 1 minute at 12 000 rpm and
the top phase was transferred into a fresh reaction vessel. Each
reaction was treated with 250 .mu.l of ethanol. The reactions were
mixed thoroughly and incubated for at least 15 minutes on dry
ice/methanol. To precipitate the RNA, the reactions were spun for
20 minutes at 12 000 rpm and 40.degree. C. The supernatant was
discarded. The pellet was dried in vacuo for 15 minutes and
resuspended in 10 .mu.l of H.sub.2O. Each reaction was treated with
10 .mu.l of denaturing loading buffer. The free GTP was separated
from the transcript formed by means of denaturing polyacrylamide
gel electrophoresis on an 8% gel with 7 M urea. The RNA transcripts
formed upon transcription with HeLa nuclear extract, in denaturing
loading buffer, were heated for 10 minutes at 90.degree. C. and 10
.mu.l aliquots were applied immediately to the freshly washed
pockets. The electrophoresis was run at 40 mA. The amount of the
radioactive ssRNA formed upon transcription was analyzed after
electrophoresis with the aid of an Instant Imager.
[0050] FIG. 3 shows the radioactive RNA from a representative test,
shown by means of the Instant Imager. Samples obtained from the
following transcription reactions were applied:
[0051] Lane 1: without template DNA, without dsRNA;
[0052] Lane 1: 50 ng of template DNA, without dsRNA;
[0053] Lane 3: 50 ng of template DNA, 0.5 .mu.g of dsRNA YFP;
[0054] Lane 4: 50 ng of template DNA, 1.5 .mu.g of dsRNA YFP;
[0055] Lane 5: 50 ng of template DNA, 3 .mu.g of dsRNA: YFP;
[0056] Land 6: 50 ng of template DNA, 5 .mu.g of dsRNA YFP;
[0057] Lane 7: without template DNA, 1.5 dsRNA YFP;
[0058] Lane 8: 50 ng of template DNA, without dsRNA;
[0059] Lane 9: 50 ng of template DNA, 0.5 .mu.g of dsRNA CMV5;
[0060] Lane 10: 50 ng of template DNA, 1.5 .mu.g of dsRNA CMV5;
[0061] Lane 11: 50 ng of template DNA, 3 .mu.g of dsRNA CMV5;
[0062] Lane 12: 50 ng of template DNA, 5 .mu.g of dsRNA CMV5;
[0063] It emerged that the amount of transcript was reduced
markedly in the presence of dsRNA with sequence homology in
comparison with the control reaction without dsRNA and with the
reactions with dsRNA YFP without sequence homology. The positive
control in lane 2 shows that radioactive transcript was formed upon
the in-vitro transcription with HeLa nuclear extract. The reaction
is used for comparison with the transcription reactions which had
been incubated in the presence of dsRNA. Lanes 3 to 6 show that the
addition of non-sequentially-specific dsRNA YFP had no effect on
the amount of transcript formed. Lanes 9 to 12 show that the
addition of an amount of between 1.5 and 3 .mu.g of
sequentially-specific dsRNA CMV5 leads to a reduction in the amount
of transcript formed. In order to exclude that the effects observed
are based not on the dsRNA but on any contamination which might
have been carried along accidentally during the preparation of the
dsRNA, a further control was carried out. Single-stranded RNA was
transcribed as described above and subsequently subjected to the
RNase treatment. It was demonstrated by means of native
polyacrylamide gel electrophoresis that the ssRNA had been degraded
completely. This reaction was subjected to phenol extraction and
ethanol precipitation and subsequently taken up in PE buffer, as
were the hybridization reactions. This gave a sample which
contained no RNA but had been treated with the same enzymes and
buffers as the dsRNA. Lane 8 shows that the addition of this sample
had no effect on transcription. The reduction of the transcript
upon addition of sequence-specific dsRNA can therefore be ascribed
unequivocally to the dsRNA itself. The reduction of the amount of
transcript of a gene in the presence of dsRNA in a human
transcription system indicates an inhibition of the expression of
the gene in question. This effect can be attributed to a novel
mechanism caused by the dsRNA.
USE EXAMPLE 2
[0064] The test system used for these in-vivo experiments was the
murine fibroblast cell line NIH3T3, ATCC CRL-1658. The YFP gene was
introduced into the nuclei with the aid of microinjection.
Expression of YFP was studied under the effect of simultaneously
cotransfected dsRNA with sequence homology. This dsRNA YFP shows
homology with the 5'-region of the YFP gene over a length of 315
bp. The nucleotide sequence of a strand of the dsRNA YRP is shown
in sequence listing No. 5. Evaluation under the fluorescence
microscope was carried out 3 hours after injection with reference
to the greenish-yellow fluorescence of the YFP formed.
Construction of the Template Plasmid, and Preparation of the
dsRNA:
[0065] A plasmid was constructed following the same principle as
described in use example 1 to act as template for the production of
the YFP dsRNA by means of T7 and SP6 in-vitro transcription. Using
the primer Eco_T7_YFP as shown in sequence listing No. 6 and
Bam_SP6_YFP as shown in sequence listing No. 7, the desired gene
fragment was amplified by PCR and used analogously to the above
description for preparing the dsRNA. The dsRNA YFP obtained is
identical to the dsRNA used in use example 1 as
non-sequence-specific control.
[0066] A dsRNA linked chemically at the 3' end of the RNA as shown
in sequence listing No. 8 to the 5' end of the complementary RNA
via a C18 linker group was prepared (L-dsRNA). To this end,
synthons modified by disulfide bridges were used. The 3'-terminal
synthon is bound to the solid support via the 3' carbon with an
aliphatic linker group via a disulfide bridge. In the 5'-terminal
synthon of the complementary oligoribonucleotide which is
complementary to the 3'-terminal synthon of the one
oligoribonucleotide, the 5'-trityl protecting group is bound via a
further aliphatic linker and a disulfide bridge. Following
synthesis of the two single strands, removal of the protecting
groups and hybridization of the complementary oligoribonucleotides,
the thiol groups which form are brought into spatial vicinity. The
single strands are linked to each other by oxidation via their
aliphatic linkers and a disulfide bridge. This is followed by
purification with the aid of HPLC.
Preparation of the Cell Cultures:
[0067] The cells were incubated in DMEM supplemented with 4.5 g/l
glucose, 10% fetal bovine serum in culture dishes at 37.degree. C.
under a 7.5% CO.sub.2 atmosphere and passaged before reaching
confluence. The cells were detached with trypsin/EDTA. To prepare
for microinjection, the cells were transferred into Petri dishes
and incubated further until microcolonies formed.
Microinjection:
[0068] For the microinjection, the culture dishes were removed from
the incubator for approximately 10 minutes. Approximately 50 nuclei
were injected singly per reaction within a marked area using the MS
microinjection system from Carl Zeiss, Gottingen, Germany. The
cells were subsequently incubated for three more hours. For the
microinjection, borosilicate glass capillaries from Hilgenberg
GmbH, Malsfeld, Germany, with a diameter of less than 0.5 .mu.m at
the tip were prepared. The microinjection was carried out using a
micromanipulator from Narishige Scientific Instrument Lab., Tokyo,
Japan. The injection time was 0.8 seconds and the pressure was
approximately 100 hPa. The transfection was carried out using the
plasmid pCDNA YFP, which contains an approximately 800 bP
BamHI/EcoRI fragment with the YFP gene in vector pcDNA3. The
samples injected into the nuclei contained 0.01 .mu.g/.mu.l of
pCDNA-YFP and Texas Red coupled to dextran-70000 in 14 mM NaCl, 3
mM KCl, 10 mM KPO.sub.4 [sic], ph 7.5. Approximately 100 pl of RNA
with a concentration of 1 .mu.M or, in the case of the L-dsRNA, 375
.mu.M were additionally added.
[0069] The cells were studied under a fluorescence microscope with
excitation with the light of the excitation wavelength of Texas
Red, 568 nm, or of YFP, 488 nm. Individual cells were documented by
means of a digital carvers. FIGS. 4a-e show the result for NIH3T3
cells. In the cells shown in FIG. 4a, sense-YFP-ssRNA has been
injected, in FIG. 4b antisense-YFP-ssRNA, in FIG. 4c dsRNA-YFP, in
FIG. 4d no RNA and in FIG. 4e L-dsRNA.
[0070] The field on the left shows in each case the fluorescence of
cells with excitation at 568 nm. The fluorescence of the same cells
at an excitation of 488 nm is seen on the right. The Texas Red
fluorescence of all the cells shown demonstrates that the injection
solution had been applied successfully into the nuclei and that
cells with successful hits were still alive after three hours. Dead
cells no longer showed Texas Red fluorescence.
[0071] The right fields of each of FIGS. 4a and 4b show that YFP
expression was not visibly inhibited when the single-stranded RNA
was injected into the nuclei. The right field of FIG. 4c shows
cells whose YFP fluorescence was no longer detectable after the
injection of dsRNA-YFP. FIG. 4d shows cells into which no RNA had
been injected, as control. The cell shown in FIG. 4e shows YFP
fluorescence which can no longer be detected owing to the injection
of the L-dsRNA which shows regions with sequence homology to the
YFP gene. This result demonstrates that even shorter dsRNAs can be
used for specifically inhibiting gene expression in mammals when
the double strands are stabilized by chemically linking the single
strands.
Sequence CWU 1
1
8145DNAArtificial SequenceDescription of Artificial Sequence EcoRI
cleavage site, T7 RNA Polymerase promoter 1ggaattctaa tacgactcac
tatagggcga tcagatctct agaag 45250DNAArtificial SequenceDescription
of Artificial Sequence BamHI cleavage site, SP6 RNA Polymerase
promoter 2gggatccatt taggtgacac tatagaatac ccatgatcgc gtagtcgata
503340RNAArtificial SequenceDescription of Artificial Sequence RNA
which corresponds to a sequence from the positive control DNA of
the HeLa Nuclear Extract in vitro transcription kit from Promega
3ucagaucucu agaagcuuua augcgguagu uuaucacagu uaaauugcua acgcagucag
60gcaccgugua ugaaaucuaa caaugcgcuc aucgucaucc ucggcaccgu cacccuggau
120gcuguaggca uaggcuuggu uaugccggua cugccgggcc ucuugcggga
uaucguccau 180uccgacagca ucgccaguca cuauggcgug cugcuagcgc
uauaugcguu gaugcaauuu 240cuaugcgcac ccguucucgg agcacugucc
gaccgcuuug gccgccgccc aguccugcuc 300gcuucgcuac uuggagccac
uaucgacuac gcgaucaugg 3404363DNAArtificial SequenceDescription of
Artificial Sequence DNA which corresponds to a sequence from the
positive control DNA of the HeLa Nuclear Extract in vitro
transcription kit from Promega 4tcagatctct agaagcttta atgcggtagt
ttatcacagt taaattgcta acgcagtcag 60gcaccgtgta tgaaatctaa caatgcgctc
atcgtcatcc tcggcaccgt caccctggat 120gctgtaggca taggcttggt
tatgccggta ctgccgggcc tcttgcggga tatcgtccat 180tccgacagca
tcgccagtca ctatggcgtg ctgctagcgc tatatgcgtt gatgcaattt
240ctatgcgcac ccgttctcgg agcactgtcc gaccgctttg gccgccgccc
agtcctgctc 300gcttcgctac ttggagccac tatcgactac gcgatcatgg
cgaccacacc cgtcctgtgg 360atc 3635315RNAArtificial
SequenceDescription of Artificial Sequence Sequence from the YFP
gene 5auggugagca agggcgagga gcuguucacc gggguggugc ccauccuggu
cgagcuggac 60ggcgacguaa acggccacaa guucagcgug uccggcgagg gcgagggcga
ugccaccuac 120ggcaagcuga cccugaaguu caucugcacc accggcaagc
ugcccgugcc cuggcccacc 180cucgugacca cccugaccua cggcgugcag
ugcuucagcc gcuaccccga ccacaugaag 240cagcacgacu ucuucaaguc
cgccaugccc gaaggcuacg uccaggagcg caccaucuuc 300uucaaggacg acggc
315652DNAArtificial SequenceDescription of Artificial Sequence
EcoRI cleavage site, T7 RNA Polymerase promoter, complementary
region to the YFP gene 6ggaattctaa tacgactcac tatagggcga atggtgagca
agggcgagga gc 52753DNAArtificial SequenceDescription of Artificial
Sequence BamHI cleavage site, SP6 RNA Polymerase promoter,
complementary region to the YFP gene 7gggatccatt taggtgacac
tatagaatac gccgtcgtcc ttgaagaaga tgg 53821RNAArtificial
SequenceDescription of Artificial Sequence RNA which corresponds to
a sequence from the YFP gene 8ucgagcugga cggcgacgua a 21
* * * * *